posted on 2025-12-16, 05:43authored byDiego J. Lopez, CJ Lodge, DS Bui, NT Waidyatillake, JC Su, JL Perret, LD Knibbs, Bircan ErbasBircan Erbas, PS Thomas, GS Hamilton, BR Thompson, MJ Abramson, EH Walters, SC Dharmage, G Bowatte, AJ Lowe
<p dir="ltr">Background: There is limited information on risk factors for eczema in adults. Recent evidence suggests that air pollution may be associated with increased incidence of eczema in adults. We aimed to assess this possible association. </p><p dir="ltr">Methods: Ambient air pollution exposures (distance from a major road, nitrogen dioxide [NO2], fine particulate matter with an aerodynamic diameter ≤2.5 µm [PM2.5]) were assessed for the residential address of Tasmanian Longitudinal Health Study participants at ages 43 and 53 years. Eczema incidence (onset after age 43 years), prevalence (at 53 years), and persistence were assessed from surveys, while IgE sensitization was assessed using skin prick tests. The presence or absence of eczema and sensitization was classified into four groups: no atopy or eczema, atopy alone, non-atopic eczema, and atopic eczema. Adjusted logistic and multinomial regression models were fitted to estimate associations between ambient air pollution and eczema, and interaction by sex was assessed. </p><p dir="ltr">Results: Of 3153 participants in both follow-ups, 2369 had valid skin prick tests. For males, a 2.3 ppb increase in baselineNO2was associated with increased odds of prevalent eczema (OR = 1.15 [95% CI 0.98–1.36]) and prevalent atopic eczema (OR = 1.26 [1.00–1.59]). These associations were not seen in females (p for interaction = 0.08, <0.01). For both sexes, a 1.6 µg/m3 increase in PM2.5 exposure at follow-up was associated with increased odds of aeroallergen sensitization (OR = 1.15 [1.03–1.30]). </p><p dir="ltr">Conclusion: Increased exposure to residential ambient air pollutants was associated with an increased odds of eczema, only in males, and aeroallergen sensitization in both genders.</p>
Funding
We acknowledge the founders of the TAHS; National Health and Medical Research Council (NHMRC) of Australia (research grants 299901 and 1021275); the University of Melbourne, Clifford Craig Medical Research Trust of Tasmania; the Victorian, Queensland, and Tasmanian Asthma Foundations; Royal Hobart Hospital; Helen MacPherson Smith Trust; GlaxoSmithKline; and John L Hopper. D. Lopez was supported by the University of Melbourne and Becas Carlos Antonio Lopez scholarship.
History
Publication Date
2021-08-01
Journal
Allergy: European Journal of Allergy and Clinical Immunology